



BIOSENSORS  
INTERNATIONAL

FOR IMMEDIATE RELEASE

## **Biosensors to Host Investor Conference Call Discussing FY 2007 Full Year Financial Results**

**Singapore, 25 April 2007** – Biosensors International Group, Ltd. (“Biosensors”, Bloomberg: BIG SP) will webcast its investor conference call discussing financial results for the fiscal fourth quarter and full fiscal year ended 31 March 2007 on **Friday, 25 May 2007, at 8:00 pm Singapore Time (8.00 am Eastern US Time)**.

The call will be hosted by Mr. Yoh-Chie Lu, CEO and Chairman and Mr. Kevin Sayer, Chief Financial Officer.

The live webcast of this call will be available at [www.biosensors.com](http://www.biosensors.com), and an archived replay will be available in the investor relations section of the Company’s website approximately three hours after the call.

A press release announcing the financial results will be issued after market closes on 25 May 2007.

## End of Release ##

### **Media & Investor Relations**

#### **Singapore**

Mr Loh Chee Mun  
Senior Vice President  
Tel: (65) 62135708  
Email: [cm.loh@biosensors.com](mailto:cm.loh@biosensors.com)

#### **United States**

##### ***Allen&Caron Inc.***

Mr. Matt Clawson  
Executive Vice President, Investor Relations  
Tel: (1) 949 474 4300  
Email: [matt@allencaron.com](mailto:matt@allencaron.com)

### **About Biosensors International Group, Ltd.**

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a bioresorbable polymer and a proprietary antirestenotic drug. It is pursuing two separate drug-eluting stent programs, *BioMatrix*<sup>™</sup> and *Axxion*<sup>™</sup>, and has licensed aspects of its drug-eluting stent technology to four companies.

### **Forward Looking Statements**

*Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.*